A Comparison of Postprandial Glucose After a Mixed Meal Tolerance Test, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study of the Dual Systemic SGLT1 and SGLT2 Inhibitor YG1699, and the Selective SGLT2 Inhibitor Dapagliflozin in Subjects With Type 1 Diabetes
Latest Information Update: 15 Dec 2022
At a glance
- Drugs YG 1699 (Primary) ; Dapagliflozin
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Youngene Therapeutics
- 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 27 Jul 2022 Status changed from recruiting to completed.
- 28 Jun 2022 Planned End Date changed from 28 Apr 2022 to 28 Jul 2022.